Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kinda looks like its going up to me.
Prove they are being investigated!
Fake news!
I totally agree. They have been nothing but transparent with their business. I’m long and strong on patriot one. $$$GLTA
Very true statement.
He never stated publicly that 453 units would be installed by the year end. And never stated of a massive rollout in 2019. He said paid pilot programs by the end of the year and roll out in Q1 of 2019
No stop sign no Byers’s beware fake news.
More fake news
Fake news.
Ok still laughing but I hope all have a very happy Thanksgiving.
Ok Dr. that statement had me laughing for hours the other day. Hahahahahahahah. Whooohooooo. Now that’s funny.
Oh Wait a minute. The KRACKEN IS BEING UNCHAINED AS WE SPEAK
As NASDAQ said before
RELEASE THE KRACKEN
Read the SEC RULES
Only if the impact is 10 percent or below. Hence no issue for Elite
All you need to do is look at their 10K’s. By SEC rules they are required to report all litigation active or pending that will have an impact on their company. Hence no news on any litigation that will impact ELITE.
So they are in the hospitality business as well. Wow we’re going to make a killing
Please please please, we all want to know what you found. I posted what I had, can’t you do the same?
Please elaborate on your findings.
Well going with your reply to n2koolaid, wouldn’t you like to do your own diligence?
Quote from you lowenstein
Re: no2koolaid Post# 303866
I find it better if I do my own diligence. That is my suggestion re elite
And no2koolaid summed it up perfectly in his post as to what he is doing and has done.
Quote from no2koolaid
“Elite has gone NOWHERE in the past 12 months? LOL, LOL...right...you mean like this NOWHERE?
Quote:
These 2 SunGen products, #3 and #4, are scheduled to be filed one month apart.
SunGen ANDA #3: 110 million
- Positive Topline BE Results announced August 14.
- File December/January
SunGen ANDA #4: ~2 Billion
- BE RESULTS ANNOUNCED ANY DAY
- File January/February
Nasrat: "We expect to keep on feeding our pipeline by filing at least the three ANDAs to substitute for the ones that get approved. So we will be filing an ANDA sometime in September/October (Completed September 18) time range and December/January and January/February, expect the three filings over the next six months or so."
Nasrat: "We have another product that we're partnering with SunGen, that’s bigger than this one." REFERRING TO ANDA #4 above.
OR MAYBE YOU MEAN THIS NOWHERE?
\
OR HOW ABOUT THIS NOWHERE?\
YOU SEE, ELITE IS A BUSINESS AND UNTIL THE BUSINESS IS ABLE TO DRIVE REVENUES FROM THE ABOVE, THAT THE P/S IS DEPRESSED DOES NOT REFLECT THE EFFORT THAT WILL LEAD TO BUSINESS SUCCESS AND, ULTIMATELY, FINANCIAL SUCCESS REFLECTED IN THE P/S. REAL BUSINESS EXECUTIVES LEARN THAT IS HOW IT WORKS! PERIOD!!! “
Looks like he get paid 1,000,000 million a year and 18,000 in competition. Doesn’t sound to bad to me.
Well here is where you can look it up. Let us know what you find
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ELITE PHARMACEUTICALS INC /NV/ income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ELITE PHARMACEUTICALS INC /NV/ annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
He’s probably a naked that got caught short.
Totally agree!!!
AMG also stated that tom Ridge made some comments on CNN this morning, ( which I can’t find anywhere )that might have something to do with the price action today. I think he’s just trying to stir something up here.
AMG also stated that time Ridge made some comments on CNN this morning, ( which I can’t find anywhere )that might have something to do with the price action today. I think he’s just trying to stir something up here.
Just replying to AMG, he stated that if we were to uplist to the NASDAQ it would require 20 to 1 split. That is totally false
How do you figure a 20 to 1 reverse split for up listing?
Thanks
Right on NASDAQ2020
Dr Aqueel is a Board Member and Operating Consultant at PLD Acquisitions LLC, a TCP portfolio company.
Blackrock acquired the company August 1 2018. Probably took a few months for Blackrock to decide it may be a conflict of interest
BlackRock Completes Acquisition of Tennenbaum Capital Partners
New York – August 1, 2018 – BlackRock, Inc. (NYSE: BLK) has completed the acquisition of Tennenbaum Capital Partners, LLC (“TCP”), bolstering BlackRock’s position as a leading global credit manager and enhancing its ability to provide clients with private credit solutions across a range of risk level, liquidity and geography.
TCP brings significant experience in middle market performing credit and special situations investing with seasoned investment talent and a strong long-term track record to the BlackRock global credit platform. Clients of both firms will benefit from enhanced scale, a broader origination network, and a premium and expanded set of private credit capabilities.
BlackRock’s Global Credit team now manages more than $90 billion in client assets across multi-strategy credit, leveraged finance, and private credit with a combined platform of more than 200 employees globally. This asset base includes TCP’s approximately $9 billion of committed client assets. TCP’s nearly 90-person team has joined BlackRock and will continue to be responsible for managing TCP products, including the investments of TCP Capital Corp. (NASDAQ: TCPC), a business development company.
The financial impact of the transaction is not material to BlackRock earnings per share. Terms were not disclosed.
About BlackRock
BlackRock helps investors build better financial futures. As a fiduciary to our clients, we provide the investment and technology solutions they need when planning for their most important goals. As of June 30, 2018, the firm managed approximately $6.3 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com | Twitter: @blackrock | Blog: www.blackrockblog.com | LinkedIn: www.linkedin.com/company/blackrock.
Contacts
Media:
Farrell Denby
(212) 810-8034 Farrell.Denby@BlackRock.com
Investor Relations:
Tom Wojcik
(212) 810-8127 Tom.Wojcik@BlackRock.com
Aqeel Fatmi
ADVISOR
Dr. Aqeel Fatmi recently retired as Chief Science Officer and Executive Vice President of Global Research and Development at Patheon and Banner Life Sciences. Prior to the acquisition of Banner by Patheon, Dr. Fatmi served on the global leadership team as Global Vice President of Research and Development, Operations and Supply Chain Management. Prior to joining Banner, Dr. Fatmi was a co-founder of the Georgia Combinatorial Chemistry Center at Georgia State University with a focus on discovering small molecule and biologics for cancer, HIV, and other infectious diseases. Dr. Fatmi spent a large part of his career at Solvay Pharmaceuticals, Inc., where he served as Vice President of Preclinical Research and Senior Vice President of Research and Development with a responsibility for the development, approval, and launch of new drugs in four therapeutic areas; namely, CNS, Cardiovascular, Gastroenterology and Hormone Replacement Therapy. Dr. Fatmi has significant experience and expertise in small molecule discovery and the development of solid orals, injectables, transdermals, abused deterrent opioids and drugs associated with rare diseases. Dr. Fatmi has more than 35 years of experience in the pharmaceutical industry with a Ph.D. in medicinal chemistry from The University of Georgia, where he also did a Post-Doctoral Fellowship in the Department of Chemistry. He is well-published and holds numerous patents. Dr. Fatmi serves on various industry and educational boards, including his current position as a Board Member and Operating Consultant at PLD Acquisitions LLC, a TCP portfolio company.
Replies:
Nice due diligence.
DR Ryan on 11/12/2018 9:40:44 PM
LOL so that PR was August 1. hmmmmmmmmmmmm
dr_lowenstein on 11/12/2018 9:44:26 PM
Report TOS
Well here is your answer.
Dr Aqueel is a Board Member and Operating Consultant at PLD Acquisitions LLC, a TCP portfolio company.
Looks like elite wasn’t lying about his resignation. Blackrock acquired the company on August first of 2018. Check it out for yourself.
BlackRock Completes Acquisition of Tennenbaum Capital Partners
New York – August 1, 2018 – BlackRock, Inc. (NYSE: BLK) has completed the acquisition of Tennenbaum Capital Partners, LLC (“TCP”), bolstering BlackRock’s position as a leading global credit manager and enhancing its ability to provide clients with private credit solutions across a range of risk level, liquidity and geography.
TCP brings significant experience in middle market performing credit and special situations investing with seasoned investment talent and a strong long-term track record to the BlackRock global credit platform. Clients of both firms will benefit from enhanced scale, a broader origination network, and a premium and expanded set of private credit capabilities.
BlackRock’s Global Credit team now manages more than $90 billion in client assets across multi-strategy credit, leveraged finance, and private credit with a combined platform of more than 200 employees globally. This asset base includes TCP’s approximately $9 billion of committed client assets. TCP’s nearly 90-person team has joined BlackRock and will continue to be responsible for managing TCP products, including the investments of TCP Capital Corp. (NASDAQ: TCPC), a business development company.
The financial impact of the transaction is not material to BlackRock earnings per share. Terms were not disclosed.
About BlackRock
BlackRock helps investors build better financial futures. As a fiduciary to our clients, we provide the investment and technology solutions they need when planning for their most important goals. As of June 30, 2018, the firm managed approximately $6.3 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com | Twitter: @blackrock | Blog: www.blackrockblog.com | LinkedIn: www.linkedin.com/company/blackrock.
Contacts
Media:
Farrell Denby
(212) 810-8034 Farrell.Denby@BlackRock.com
Investor Relations:
Tom Wojcik
(212) 810-8127 Tom.Wojcik@BlackRock.com
Aqeel Fatmi
ADVISOR
Dr. Aqeel Fatmi recently retired as Chief Science Officer and Executive Vice President of Global Research and Development at Patheon and Banner Life Sciences. Prior to the acquisition of Banner by Patheon, Dr. Fatmi served on the global leadership team as Global Vice President of Research and Development, Operations and Supply Chain Management. Prior to joining Banner, Dr. Fatmi was a co-founder of the Georgia Combinatorial Chemistry Center at Georgia State University with a focus on discovering small molecule and biologics for cancer, HIV, and other infectious diseases. Dr. Fatmi spent a large part of his career at Solvay Pharmaceuticals, Inc., where he served as Vice President of Preclinical Research and Senior Vice President of Research and Development with a responsibility for the development, approval, and launch of new drugs in four therapeutic areas; namely, CNS, Cardiovascular, Gastroenterology and Hormone Replacement Therapy. Dr. Fatmi has significant experience and expertise in small molecule discovery and the development of solid orals, injectables, transdermals, abused deterrent opioids and drugs associated with rare diseases. Dr. Fatmi has more than 35 years of experience in the pharmaceutical industry with a Ph.D. in medicinal chemistry from The University of Georgia, where he also did a Post-Doctoral Fellowship in the Department of Chemistry. He is well-published and holds numerous patents. Dr. Fatmi serves on various industry and educational boards, including his current position as a Board Member and Operating Consultant at PLD Acquisitions LLC, a TCP portfolio company.
Why don’t you call Dianne and ask her for the letter. Here’s her contact info.
Dianne Will
Telephone: 518-398-6222
Email: dianne@elitepharma.com
News is out. Elite launches methadone with Glenmark. Whooohooo go elite
Thats 10,000 sales leads. But I believe from a previous PR they put out they have a 450 unit backlog, but please check it out for yourself
Just checked it out, you’re right. That’s a good thing.
Links please. Thanks
The news smells pretty greeeeeen to me. GLTO$$$
I hope the Shortys get squeezed like a big dog in a little house.
And also an ad do a product manager.